Cargando…

液体活检在小细胞肺癌诊疗中的应用研究进展

Small cell lung cancer (SCLC) is a malignant tumor with strong invasiveness and high mortality. It has the characteristics of easy metastasis, fast growth, high degree of malignancy and strong invasiveness. The prognosis of patients is generally poor. The current clinical diagnosis of SCLC is mainly...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411954/
https://www.ncbi.nlm.nih.gov/pubmed/36002198
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.22
_version_ 1784775382558310400
collection PubMed
description Small cell lung cancer (SCLC) is a malignant tumor with strong invasiveness and high mortality. It has the characteristics of easy metastasis, fast growth, high degree of malignancy and strong invasiveness. The prognosis of patients is generally poor. The current clinical diagnosis of SCLC is mainly based on tissue biopsy, which is invasive, long cycle time and high cost. In recent years, liquid biopsy has been gradually applied because of its non-invasive, comprehensive and real-time characteristics that traditional tissue biopsy does not have. The main detection objects of liquid biopsy include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes in peripheral blood. The application of liquid biopsy in the clinical treatment of SCLC will help clinicians to improve the detailed diagnosis of SCLC patients, as well as the timely control and response to the treatment response of patients.
format Online
Article
Text
id pubmed-9411954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-94119542022-09-12 液体活检在小细胞肺癌诊疗中的应用研究进展 Zhongguo Fei Ai Za Zhi 综述 Small cell lung cancer (SCLC) is a malignant tumor with strong invasiveness and high mortality. It has the characteristics of easy metastasis, fast growth, high degree of malignancy and strong invasiveness. The prognosis of patients is generally poor. The current clinical diagnosis of SCLC is mainly based on tissue biopsy, which is invasive, long cycle time and high cost. In recent years, liquid biopsy has been gradually applied because of its non-invasive, comprehensive and real-time characteristics that traditional tissue biopsy does not have. The main detection objects of liquid biopsy include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosomes in peripheral blood. The application of liquid biopsy in the clinical treatment of SCLC will help clinicians to improve the detailed diagnosis of SCLC patients, as well as the timely control and response to the treatment response of patients. 中国肺癌杂志编辑部 2022-08-20 /pmc/articles/PMC9411954/ /pubmed/36002198 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.22 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
液体活检在小细胞肺癌诊疗中的应用研究进展
title 液体活检在小细胞肺癌诊疗中的应用研究进展
title_full 液体活检在小细胞肺癌诊疗中的应用研究进展
title_fullStr 液体活检在小细胞肺癌诊疗中的应用研究进展
title_full_unstemmed 液体活检在小细胞肺癌诊疗中的应用研究进展
title_short 液体活检在小细胞肺癌诊疗中的应用研究进展
title_sort 液体活检在小细胞肺癌诊疗中的应用研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411954/
https://www.ncbi.nlm.nih.gov/pubmed/36002198
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.22
work_keys_str_mv AT yètǐhuójiǎnzàixiǎoxìbāofèiáizhěnliáozhōngdeyīngyòngyánjiūjìnzhǎn
AT yètǐhuójiǎnzàixiǎoxìbāofèiáizhěnliáozhōngdeyīngyòngyánjiūjìnzhǎn
AT yètǐhuójiǎnzàixiǎoxìbāofèiáizhěnliáozhōngdeyīngyòngyánjiūjìnzhǎn
AT yètǐhuójiǎnzàixiǎoxìbāofèiáizhěnliáozhōngdeyīngyòngyánjiūjìnzhǎn